402-P: Effect of Serum 25-Hydroxyvitamin D on CKD Progression in Type 2 diabetes

• Published in: Diabetes (New York, N.Y.) Vol. 73; p. 1
• Main Authors: Zhang, Chenghui, Suyuan, Wang, Li, Mingxia
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2024
• Subjects: 25-Hydroxyvitamin D; Blood pressure; Diabetes; Diabetes mellitus (non-insulin dependent); End-stage renal disease; Kidney diseases; Low density lipoprotein; Vitamin D
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db24-402-P

Background: It has been established that there was an inverse association between baseline serum 25-hydroxyvitamin D (25OHD) and new-onset chronic kidney disease (CKD) in patients with type 2 diabetes (T2D). However, the prospective relationship between vitamin D status and CKD progression remains uncertain. We aimed to investigate the association between 25OHD level and the progression of CKD in patients with T2D. Methods: In this prospective, observational study, patients with T2D aged 18-79, who had received regular medical examination for at least a year were consecutively enrolled. Physical findings and laboratory data of patients were collected annually. Serum 25OHD concentrations were measured using chemiluminescent immunoassay method. The primary outcome was CKD progression, defined as a change of at least 1 CKD stage or incidence of macroalbuminuria or new-onset end-stage renal disease. The risk of CKD progression according to 25OHD was analyzed by Cox proportional hazard models. Results: A total of 245 patients were enrolled in this study. The mean age was 59 years, with a majority of 179 (73%) being male participants. The baseline 25OHD connection was measured at 16.4 (7.1) ng/ml. Over a median follow-up period of 2.1 years, 38 subjects (16.5%) developed CKD progression. After adjusting for gender, age, diabetic duration, BMI, systolic blood pressure, HbA1c, LDL-C, baseline eGFR, serum concentrations of 25OHD was associated with 7% lower risk of CKD progression per every 1ng/ml increase (HR: 0.93, 95%CI: 0.86-0.99, P=0.036). Conclusion: Serum 25OHD was found to be an independent protective factor for CKD progression in patients with type 2 diabetes.